What Viatris's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Viatris filed its latest 10-Q with the SEC on Nov 5, 2026. It discusses acquisition announced, cost reduction and divestiture.
Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn
Get Viatris' live signals in Claude or ChatGPT, or by API
What changed at Viatris this week? Use Autobound signals for viatris.com.- Filed
- Nov 5, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 16
Source: Autobound Signal API · 76 signals tracked for Viatris · updated
10-Q · latest 10
What Viatris's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
Viatris to acquire Pacira for $36.50 per share in cash, totaling $1.65 billion
Viatris entered into a merger agreement on October 8, 2026, to acquire all outstanding shares of Pacira for $36.50 per share in cash, or approximately $1.65 billion.
$1.7B
aggregate equity value for the acquisition of Pacira
Nashik facility suspended following fire and FDA OAI rating, impacting revenue $100M
Viatris voluntarily suspended manufacturing at its Nashik facility in October 2026 after receiving an FDA OAI classification, causing an estimated $100 million revenue hit in Q3 2026 and another $100 million anticipated in Q4 2026.
$100M
estimated negative impact of product supply to total revenues in the third quarter of 2026
Viatris completes sale of Biocon equity position for approximately $380 million
On July 14, 2026, Viatris completed the sale of its equity position in Biocon for pre-tax total consideration of approximately $380 million following the earlier disposition of CCPS in Biocon Biologics.
$380M
pre-tax total consideration from the sale of Biocon equity position
-2.7%
block sale discount to market
Viatris targets $600M to $700M in savings from enterprise-wide restructuring program
Viatris expects potential savings of $600 million to $700 million once its committed restructuring activities are fully implemented through 2028.
$600M
minimum potential savings from committed restructuring activities
FDA classifies Nashik facility inspection as OAI following May 2026 Form 483 observations
In September 2026, Viatris received notice from the FDA that its oral solid dose facility in Nashik, India was classified as Official Action Indicated (OAI).
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 5 signals
Viatris sells Biocon equity stake on July 14, 2026 for approximately $380 million
Viatris completed the sale of its equity position in Biocon on July 14, 2026 for pre-tax total consideration of approximately $380 million, following the earlier sale of CCPS in Biocon Biologics.
$380M
pre-tax total consideration from the sale of its equity position in Biocon
Viatris plans workforce reduction of up to approximately 10% under enterprise-wide strategic review
Viatris announced restructuring activities under its EWSR that include an expected global workforce reduction of up to approximately 10% over the next three years.
-10%
global workforce reduction
Fire and FDA Form 483 at Nashik plant causes $100M-$150M revenue disruption
A fire in February 2026 and subsequent FDA Form 483 observations at the Nashik, India oral solid dose facility caused intermittent disruptions expected to hit H2 2026 revenue by $100 million to $150 million.
$150M
anticipated impact of product supply disruptions on total revenues in H2 2026
Viatris targets $600M to $700M in savings via Enterprise-Wide Strategic Review restructuring
Viatris committed to restructuring activities under its EWSR expected to deliver between $600 million and $700 million in potential savings once fully implemented over the next three years.
$600M
potential savings from committed restructuring activities
Viatris launched EWSR restructuring targeting $600M to $700M in potential savings
Viatris committed to restructuring commercial capabilities, R&D, supply chain, and sourcing under an EWSR, expecting $700M to $850M in pre-tax charges and $600M to $700M in run-rate savings.
$700M
potential savings from committed restructuring activities
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 6 signalsSEC EDGAR
Showing 10 of 16 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Viatris earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 revenue of $3.75B with 2% nine-month operational growthDelivered total Q3 revenues of $3.75B and adjusted EBITDA of $1.2B with a 58% adjusted gross margin. Through the first 9 months of 2026, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally. Strong performance in Greater China and North America offset supply constraints affecting lower-margin generics in Europe and emerging markets. | |
| Agreement to acquire Pacira BioSciences closing in November 2026Launched a tender offer on October 30 to acquire Pacira BioSciences, scheduled to close before the end of November 2026 funded by excess cash and credit lines. The transaction adds patent-protected medicines EXPAREL and ZILRETTA, supporting an expected $1B+ in 2027 U.S. innovative medicine revenue and over $50M in annual cost synergies by 2028. The deal also expands commercial sales, medical... | |
| Full year 2026 financial guidance raised across all key metricsManagement narrowed guidance ranges and raised midpoints for full year 2026 financial metrics based on year-to-date performance. Revised midpoint expectations call for operational growth of 2% in revenue, 6% in adjusted EBITDA, and 8% in adjusted EPS, excluding Pacira contributions. This outlook balances Q4 supply disruptions of $100M in Europe and emerging markets against accelerating North... | |
| North America net sales up 7% driven by complex genericsQ3 North America net sales grew 7% year-over-year, driven by high-margin complex generics and doubled volumes of estradiol patch products. Complex generics and estradiol patches accounted for over 65% of North American generics net sales during the quarter. Full-year 2026 regional guidance was revised upward from flat to high single-digit growth. | |
| Commercial launch of Gwyn Lo patch and multiple approvalsLaunched Gwyn Lo low-dose contraceptive patch in the U.S. in October 2026 and preparing for once-monthly aripiprazole injection launch. Also secured U.S. FDA approval for Ryzumvi for presbyopia and Japanese regulatory approval for Wakix. The company is tracking more than 100 new product approvals in 2026 and preparing for a potential early 2027 U.S. launch of fast-acting meloxicam pending a... | |
| Nashik facility suspension causes $100M quarterly revenue impactViatris suspended manufacturing at its Nashik facility following FDA 483 observations and an Official Action Indicated (OAI) classification. The resulting supply constraints reduced Q3 revenue by approximately $100 million and are projected to cause another $100 million headwind in Q4 across Europe and emerging markets. This disruption creates opportunities for supply chain remediation... |
Signal API · MCP
Track Viatris with the Signal API
One POST /v1/companies/enrich call with viatris.com returns Viatris 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Viatris 10-Q
When did Viatris file its latest 10-Q?
What did Viatris disclose in its latest 10-Q?
What did Viatris say on its recent earnings calls?
Where can I read Viatris's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .